ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Diagnostic and Prognostic Values of Bile Biomarkers for Malignant Biliary Stenosis.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic and Prognostic Values of Bile Biomarkers for Malignant Biliary Stenosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDifferentiating between malignant and benign biliary strictures remains a clinical challenge because current diagnostic tools have limited sensitivity. The detection of tumour-related biomarkers directly in bile, which is in close contact with the lesion, may enhance diagnostic accuracy. This study aimed at evaluating the diagnostic and prognostic values of biliary concentrations of VEGF, PDGF-AA, IGF and MMPs in patients with extrahepatic cholangiocarcinoma (CCA), pancreatic ductal adenocarcinoma (PDAC), or benign obstruction.
methodsA total of 100 consecutive patients undergoing ERCP for obstructive jaundice were enrolled and categorised into benign (n = 48), CCA (n = 23) and PDAC (n = 29) groups. Bile samples collected during ERCP were analysed. The diagnostic and prognostic performance of several biomarkers was assessed and, when appropriate, their incremental diagnostic value was assessed in comparison with standard bile cytology.
resultsBiliary concentrations of VEGF, MMP-1, MMP-2, MMP-7 and MMP-9 were significantly higher in malignant cases than in benign cases. VEGF demonstrated the best diagnostic accuracy (AUROC 0.86, sensitivity 87%, specificity 81%). MMP-1 and MMP-7 also showed good diagnostic values (AUROCs 0.79 and 0.81 respectively). In the multivariate analysis, VEGF was independently associated with the diagnosis of malignancy and PDAC, whereas both VEGF and MMP-2 were independently associated with CCA diagnosis. Using a predefined cut-off, bile VEGF showed a higher sensitivity than bile cytology, and their combination markedly reduced false-negative results. Regarding prognosis, higher PDGF-AA levels were independently associated with better survival rates.
conclusionBiliary VEGF is a strong independent biomarker for the diagnosis of malignant biliary obstruction, both in PDAC and CCA. MMP-2 was independently associated with CCA diagnosis. PDGF-AA is a promising prognostic biomarker for malignant biliary strictures. These findings support the clinical potential of bile-based biomarkers for improving the diagnosis and assessing the prognosis of malignant biliary strictures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.